Ahlam Salameh

Dr. Ahlam Salameh

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
ASAhlam Salameh
Ahlam Salameh
JMJessica McCabe
Jessica McCabe
MSMargaret Skelly
Margaret Skelly
KDKelsey Rose Duncan
Kelsey Rose Duncan
ZCZhengyi Chen
Zhengyi Chen
SPSvetlana Pundik
Svetlana Pundik
Gait deficits are often persistent after stroke, and current rehabilitation methods do not restore normal gait for everyone. Targeted methods of focused gait therapy that meet the individual needs of each stroke survivor are needed. Our objective was to develop and test a combination protocol of simultaneous brain stimulation and focused stance phase training for people with chronic stroke (>6 months). We combined Transcranial Direct Current Stimulation (tDCS) with targeted stance phase therapy using Virtual Reality (VR)-assisted treadmill training and overground practice. The training was guided by motor learning principles. Five users (>6 months post-stroke with stance phase gait deficits) completed 10 treatment sessions. Each session began with 30 min of VR-assisted treadmill training designed to apply motor learning (ML)-based stance phase targeted practice. During the first 15 min of the treadmill training, bihemispheric tDCS was simultaneously delivered. Immediately after, users completed 30 min of overground (ML)-based gait training. The outcomes included the feasibility of protocol administration, gait speed, Timed Up and Go (TUG), Functional Gait Assessment (FGA), paretic limb stance phase control capability, and the Fugl–Meyer for lower extremity coordination (FMLE). The changes in the outcome measures (except the assessments of stance phase control capability) were calculated as the difference from baseline. Statistically and clinically significant improvements were observed after 10 treatment sessions in gait speed (0.25 ± 0.11 m/s) and FGA (4.55 ± 3.08 points). Statistically significant improvements were observed in TUG (2.36 ± 3.81 s) and FMLE (4.08 ± 1.82 points). A 10-session intervention combining tDCS and ML-based task-specific gait rehabilitation was feasible and produced clinically meaningful improvements in lower limb function in people with chronic gait deficits after stroke. Because only five users tested the new protocol, the results cannot be generalized to the whole population. As a contribution to the field, we developed and tested a protocol combining brain stimulation and ML-based stance phase training for individuals with chronic stance phase deficits after stroke. The protocol was feasible to administer; statistically and/or clinically significant improvements in gait function across an array of gait performance measures were observed with this relatively short treatment protocol.

28 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
PZPan Zhao
Pan Zhao
RGRobert Ryan Geyer
Robert Ryan Geyer
ASAhlam Salameh
Ahlam Salameh
AWAmanda B Wass
Amanda B Wass
STSara Taki
Sara Taki
WBWalter F. F. Boron
Walter F. F. Boron
Many have believed that oxygen (O 2 ) crosses red blood cell (RBC) membranes by dissolving in lipids that offer no resistance to diffusion. However, using stopped-flow (SF) analyses of hemoglobin (Hb) absorbance spectra during O 2 off-loading from mouse RBCs, we now report that most O 2 traverses membrane-protein channels. Two agents excluded from the RBC interior markedly slow O 2 off-loading: p-chloromercuribenzenesulfonate (pCMBS) reduces inferred membrane O 2 permeability ( P Membrane ) by ∼82%, and 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS), by ∼56%. Because neither likely produces these effects via membrane lipids, we examined RBCs from mice genetically deficient in aquaporin-1 (AQP1), the Rh complex (i.e., rhesus proteins RhAG + mRh), or both. The double knockout (dKO) reduces P Membrane by ∼55%, and pCMBS+dKO, by ∼91%. Proteomic analyses of RBC membranes, flow cytometry, hematology, and mathematical simulations rule out explanations involving other membrane proteins, RBC geometry, or extracellular unconvected fluid (EUF). By identifying the first two O 2 channels and pointing to the existence of other O 2 channel(s), all of which could be subject to physiological regulation and pharmacological intervention, our work represents a paradigm shift for O 2 handling.

10 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
FMFraser John Moss
Fraser John Moss
PZPan Zhao
Pan Zhao
ASAhlam Salameh
Ahlam Salameh
STSara Taki
Sara Taki
AWAmanda B Wass
Amanda B Wass
WBWalter F. F. Boron
Walter F. F. Boron
In this second of three papers, we examine red blood cell (RBC) morphometry and RBC-membrane proteomics from our laboratory mouse strain (C57BL/6 Case ). In paper #1 , using stopped-flow absorbance spectroscopy to ascertain the rate constant for oxyhemoglobin (HbO 2 ) deoxygenation ( k HbO 2 ), we find substantial k HbO 2 reductions with (1) membrane-protein inhibitors p-chloromercuribenzenesulfonate (pCMBS) or 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS); (2) knockouts of aquaporin-1 (AQP1-KO), or Rhesus blood-group–associated A-glycoprotein (RhAG-KO), or double knockouts (dKO); or (3) inhibitor+dKO. In paper #3 , reaction-diffusion mathematical modeling/simulations reveal that k HbO 2 could fall secondary to slowed intracellular O 2 /HbO 2 /Hb diffusion. Here in paper #2 , blood smears as well as still/video images and imaging flow cytometry (IFC) of living RBCs show that ∼97.5% to ∼98.6% of control (not drug-treated) cells are biconcave disks (BCDs) across all genotypes. Pretreatment with pCMBS raises non-BCD abundance to ∼8.7% for WT and ∼5.7% for dKO; for DIDS pretreatment, the figures are ∼41% and ∼21%, respectively. Modeling ( paper #3 ) accommodates for these shape changes. Light-scattering flow cytometry shows no significant difference in RBC size or shape among genotypes. IFC reveals minor differences among genotypes in RBC major diameter (Ø Major ), which (along with mean corpuscular volume, paper #1 ) yields RBC thickness for simulations in paper #3. Label-free liquid chromatography/tandem mass spectrometry (LC/MS/MS) proteomic analyses of RBC plasma-membrane ghosts confirm the deletion of proteins targeted by our knockouts, and rule out changes in the 100 proteins of greatest inferred abundance. Thus, genetically induced changes in k HbO 2 must reflect altered abundance of AQP1 and /or the Rh complex. Key Points: O 2 -offloading from red blood cells (RBCs) depends not only on membrane O 2 permeability and oxyhemoglobin dissociation, but also on RBC size and shape. In this second of three papers, we use blood smears, still/video images of living RBCs, and imaging flow cytometry to examine morphometry of RBCs from paper #1 . We find that mouse RBCs of all genotypes—wild-type, aquaporin-1 knockout (AQP1-KO), Rhesus blood group-associated A-glycoprotein knockout (RhAG-KO), and double knockout—are dominantly biconcave discs, with ∼1.4% to ∼2.5% poikilocytosis (shape change, SC). Drug pre-treatment increases %SC. Using label-free liquid chromatography/tandem mass spectrometry to assess apparent abundance of RBC-ghost proteins, we find no significant differences among genotypes for any of the ∼100 most abundant protein species except, as appropriate, AQP1, RhAG, or Rhesus blood group D antigen. Thus, the substantial effects observed in paper #1 cannot be attributed to differences in morphometry or protein content.

8 May 2026 in Stroke
Verified
Journal Article
Closed access
CCChristy Cassarly
Christy Cassarly
SISalman Ikramuddin
Salman Ikramuddin
GSGottfried Schlaug
Gottfried Schlaug
ASAhlam Salameh
Ahlam Salameh
SWSteven L. Wolf
Steven L. Wolf
WFWuwei Feng
Wuwei Feng
Over the past 2 decades, transcranial direct current stimulation has attracted substantial interest as an adjunctive strategy to enhance poststroke motor recovery. In addition to its potential neuromodulatory effects on motor cortical networks, transcranial direct current stimulation devices are low-cost, easy to use, and compatible with concurrent rehabilitation. Yet, despite its promise, several barriers hinder translation into routine clinical practice, including neutral results from several recently completed multicenter trials, such as TRANSPORT2 (Transcranial Direct Current Stimulation for Post-Stroke Motor Recovery). Moving forward, progress will depend on addressing issues in 3 broad domains: device-related (stimulation parameters and montage), disease-related (patient characteristics and timing), and trial design (outcomes, analytical approaches, adjunctive therapy, and trial infrastructure). In this topical review, we critically examine these challenges and outline strategies to refine transcranial direct current stimulation application, with the goal of more effectively leveraging its neuromodulation properties to promote neuroplasticity and enhance motor recovery after stroke.

29 May 2026 in Brain Stimulation
Verified
Journal Article
Open access
SPSvetlana Pundik
Svetlana Pundik
MSMargaret Skelly
Margaret Skelly
ASAhlam Salameh
Ahlam Salameh
LLLisa Leonhardt
Lisa Leonhardt
EHElizabeth C. Hardin
Elizabeth C. Hardin
JMJessica McCabe
Jessica McCabe
Persistent gait deficits after stroke are prevalent and negatively impact function. Motor learning methods promote neuroplasticity and can produce significant clinical gains, however recovery is limited for many individuals in the chronic phase. Transcranial direct current stimulation(tDCS) can enhance neuroplastic effects of training and can be easily paired with neurorehabilitation. We tested active vs. sham bihemispheric 2 mA tDCS targeting primary motor leg regions paired with gait therapy. Individuals(n = 44) were randomized to 10 sessions of active tDCS/sham tDCS paired with motor training. Outcomes were collected at baseline, mid-treatment, post-treatment and 6-week follow-up. TDCS-induced electric field(e-field) and lesion load were calculated using each participant's magnetic resonance imaging (MRI). Statistical methods included longitudinal linear mixed-effects model with treatment group by time interaction effects, Wilcoxon signed rank test and correlation analyses. Thirty-nine individuals completed the study. No difference was observed between treatment groups. Total cohort analysis showed significant improvement (p < 0.05) in the following: Fugl-Meyer, fastest gait speed, preferred gait speed, Timed Up and Go, Functional Gait Assessment, and Gait Assessment and Intervention Tool across time, with maintenance or improvement at 6-week follow-up. E-field in targeted region ranged 0.10-0.29 V/m. Lesion load did not correlate with change in clinical outcomes. Both groups improved across the clinical outcomes following short duration motor learning-based gait training with and without tDCS. Lesion load was not related to treatment response. E-field in targeted regions was variable across participants. Future studies employing optimized tDCS to ensure consistent dosing across subjects, paired with an effective gait training approach is needed.

18 January 2013 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
ABA. Bader
A. Bader
ABA. Brodarac
A. Brodarac
RHR. Hetzer
R. Hetzer
AKA. Kurtz
A. Kurtz
Christof StammChristof Stamm
Christof Stamm
RAR. Alt
R. Alt
CD133pos cells are currently evaluated for use in cardiac cell therapy. We hypothesized that they exert their beneficial effects in a paracrine manner and investigated this in a cell culture ischaemia model. Furthermore, we checked whether purified CD133pos cells perform better than non-fractionated mononuclear cells (MNC).